Dr. Paul Lammers, the Chief Executive Officer at Triumvira Immunologics, is developing personalized medicine to treat solid tumors using an autologous approach to arm the patient-derived cells with a vector that identifies and kills individual cancer cells. At the forefront of the next generation of immune-oncology, Triumvira uses the Cocoon Platform made by Lonza to automate this process in a closed system to grow and harvest the cells. The ultimate goal is to have this technology available at the point of care in regional cancer centers to allow this cell therapy to be used by more cancer patients.
Paul elaborates, “The challenge with T cell therapy has been can we also use cell therapy to treat solid tumors? And that’s where we feel that with our technology, known as TAC, T Cell Antigen Coupler comes in. We truly think we have an opportunity here, so we feel we are developing first-in-class medications based on that new T cell engineer platform, the TAC. We hope to have an opportunity to focus on different types of targets in solid tumors that will address high unmet needs in cancers like gastric cancer and colorectal cancer and pancreatic cancer, and ovarian and endometrial.”
